The recommendation comes as competition between Novo and Lilly intensifies, with both companies seeking to grow their share of the booming obesity drug market, which analysts expect to reach over a $100 billion annually in the next decade, by expanding into oral treatments
Frediani, PhD, RD, ACSM-CES, is a nutrition scientist, exercise physiologist, and registered dietitian with over two decades of experience in clinical research, educati
By targeting both receptors, tirzepatide produces complementary effects: Dual appetite regulation: Like semaglutide, tirzepatide activates GLP-1 receptors in the brain to suppress appetite and slow gastric emptying
How do the injectable and oral forms compare on timing flexibility
Can I still get "Compounded Semaglutide" in 2026